401 related articles for article (PubMed ID: 19217031)
21. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors.
Berger U; Wilson P; Thethi S; McClelland RA; Greene GL; Coombes RC
Cancer Res; 1989 Sep; 49(18):5176-9. PubMed ID: 2766287
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
23. [Human breast cancer embedded in paraffin, fixed in Bouin's fluid. Immunohistochemical analysis of estrogen and progesterone receptors].
Jacquemier J; Boudaoura T; Martin PM; Torrente M; Hassoun J
Ann Pathol; 1991; 11(4):224-30. PubMed ID: 1958256
[TBL] [Abstract][Full Text] [Related]
24. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
25. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
[TBL] [Abstract][Full Text] [Related]
26. HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma.
Ramalho S; Serra KP; Vassallo J; Soares FA; Pinto GA; Teixeira LC; da Cunha IW; Derchain SF; de Souza G
Acta Histochem; 2013 Mar; 115(2):120-7. PubMed ID: 22647460
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
Birner P; Oberhuber G; Stani J; Reithofer C; Samonigg H; Hausmaninger H; Kubista E; Kwasny W; Kandioler-Eckersberger D; Gnant M; Jakesz R;
Clin Cancer Res; 2001 Jun; 7(6):1669-75. PubMed ID: 11410505
[TBL] [Abstract][Full Text] [Related]
28. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.
Sharangpani GM; Joshi AS; Porter K; Deshpande AS; Keyhani S; Naik GA; Gholap AS; Barsky SH
J Microsc; 2007 Jun; 226(Pt 3):244-55. PubMed ID: 17535263
[TBL] [Abstract][Full Text] [Related]
29. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
[TBL] [Abstract][Full Text] [Related]
30. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
[TBL] [Abstract][Full Text] [Related]
31. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
[TBL] [Abstract][Full Text] [Related]
33. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
Park MM; Ebel JJ; Zhao W; Zynger DL
Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
[TBL] [Abstract][Full Text] [Related]
34. Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in nonmalignant and malignant breast disorders.
Charpin C; Jacquemier J; Andrac L; Vacheret H; Habib MC; Devictor B; Lavaut MN; Toga M
Am J Pathol; 1988 Aug; 132(2):199-211. PubMed ID: 2456699
[TBL] [Abstract][Full Text] [Related]
35. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma.
Jain V; Landry M; Levine EA
Am Surg; 1996 Feb; 62(2):162-5. PubMed ID: 8554195
[TBL] [Abstract][Full Text] [Related]
36. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV
Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992
[TBL] [Abstract][Full Text] [Related]
37. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
Skaland I; Øvestad I; Janssen EA; Klos J; Kjellevold KH; Helliesen T; Baak JP
J Clin Pathol; 2008 Jan; 61(1):68-71. PubMed ID: 17412872
[TBL] [Abstract][Full Text] [Related]
38. Quantitative assessment of oestrogen and progesterone receptors on fine-needle aspirates and cryostat sections of breast carcinomas: how does this compare with biochemical assays?
Muchiri LW
East Afr Med J; 1993 May; 70(5):280-3. PubMed ID: 8306903
[TBL] [Abstract][Full Text] [Related]
39. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
[TBL] [Abstract][Full Text] [Related]
40. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
